CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 1,601 enrolled
Drug / intervention
BAY2433334 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04304534
NCT04304534Phase 2Completed
CompareCT.gov

Multicenter, Randomized, Placebo Controlled, Double-blind, Parallel Group, Dose-finding Phase 2 Study to Evaluate the Efficacy and Safety of BAY 2433334 in Patients Following an Acute Myocardial Infarction

Bayer·interventional·Posted Mar 11, 2020·Updated Apr 5, 2023

In Brief

A Phase 2 clinical trial evaluating BAY2433334 and BAY2433334 matching placebo for Acute Myocardial Infarction. Completed, enrolled 1,601 participants across 160 sites in 14 countries.

Detailed Summary

The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of a dual antiplatelet therapy (acetylsalicylic acid +/- clopidogrel) in patients following a recent heart attack (myocardial infarction) that happens when a blood vessel in the heart suddenly becomes blocked. BAY 2433334, works by blocking a step of the blood clotting process in our body and thins the blood and is a so called oral FXIa inhibitor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myocardial Infarction
CountriesAustria, Belgium, Czechia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Spain, Sweden, Switzerland, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedMar 11, 2020
Enrollment StartJun 17, 2020
Primary CompletionFeb 21, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.3 years ago

Interventions

BAY2433334drug

Tablet, taken orally once a day.

BAY2433334 matching placeboother

Tablet, taken orally once a day.